Nakano Youichirou, Kusama Nobuyoshi, Kajikuri Junko, Suzuki Yoshikatsu, Kanmura Yuichi, Itoh Takeo
Department of Cellular and Molecular Pharmacology,Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
Br J Pharmacol. 2004 Feb;141(3):391-8. doi: 10.1038/sj.bjp.0705625. Epub 2004 Jan 12.
We examined whether 10 days' in vivo treatment with glyceryl trinitrate (GTN) might reduce cGMP-induced relaxation in the smooth muscle of rabbit mesenteric resistance arteries and, if so, whether protein kinase C (PKC) plays a role in this downregulation. The relaxation responses to GTN and the nitric oxide donor NOC-7 were significantly reduced in endothelium-denuded strips from GTN-treated rabbits. In beta-escin-skinned smooth muscle, the ability of 8-bromoguanosine 3',5' cyclic monophosphate (8-Br-cGMP, a phosphodiesterase-resistant cGMP analogue) to relax the contraction induced by 0.3 microM Ca2+ was significantly reduced in GTN-treated rabbits. In beta-escin-skinned smooth muscle, an inhibitor of conventional and/or novel PKCs, GF109203X (0.6 microM), inhibited the Ca2+ -induced contraction and enhanced the 8-Br-cGMP-induced relaxation. However, since the relaxing ability of 8-Br-cGMP was found to be unchanged by GF109203X when contractions were amplitude-matched (0.2 microM Ca2+ alone vs 0.3 microm Ca2+ + GF109203X), the increase in the 8-Br-cGMP-response seen with GF109203X was probably due to its inhibitory action on the Ca2+ -induced contraction. Furthermore, although the PKC activator phorbol 12,13-dibutyrate (PDBu, 0.1 microM) decreased the 8-Br-cGMP-induced relaxation of the Ca2+ (0.3 microM) contraction, this was probably due to its enhancement of the Ca2+ -induced contraction since no such effect of PDBu was seen when the Ca2+ -induced contractions were amplitude-matched (0.2 microM Ca2+ + PDBu vs 0.3 microM Ca2+ alone). These results suggest that the relaxing response to cGMP is reduced in the smooth muscle of mesenteric resistance arteries in GTN-treated rabbits but that conventional and/or novel PKCs do not play a major role in maintaining this downregulation. British Journal of Pharmacology (2004) 141, 391-398. doi:10.1038/sj.bjp.0705625
我们研究了用硝酸甘油(GTN)进行10天的体内治疗是否会降低兔肠系膜阻力动脉平滑肌中cGMP诱导的舒张作用,如果是这样,蛋白激酶C(PKC)是否在这种下调中起作用。来自GTN治疗兔的内皮剥脱条对GTN和一氧化氮供体NOC-7的舒张反应显著降低。在β-七叶皂苷处理的平滑肌中,8-溴鸟苷3',5'-环磷酸(8-Br-cGMP,一种抗磷酸二酯酶的cGMP类似物)舒张0.3微摩尔Ca2+诱导收缩的能力在GTN治疗的兔中显著降低。在β-七叶皂苷处理的平滑肌中,一种传统和/或新型PKC的抑制剂GF109203X(0.6微摩尔)抑制了Ca2+诱导的收缩并增强了8-Br-cGMP诱导的舒张。然而,由于当收缩幅度匹配时(仅0.2微摩尔Ca2+与0.3微摩尔Ca2+ + GF109203X),发现GF109203X并未改变8-Br-cGMP的舒张能力,因此GF109203X所见的8-Br-cGMP反应增加可能是由于其对Ca2+诱导收缩的抑制作用。此外,尽管PKC激活剂佛波醇12,13-二丁酸酯(PDBu,0.1微摩尔)降低了8-Br-cGMP诱导的Ca2+(0.3微摩尔)收缩的舒张,但这可能是由于其增强了Ca2+诱导的收缩,因为当Ca2+诱导的收缩幅度匹配时(0.2微摩尔Ca2+ + PDBu与仅0.3微摩尔Ca2+)未观察到PDBu的这种作用。这些结果表明,在GTN治疗的兔中,肠系膜阻力动脉平滑肌对cGMP的舒张反应降低,但传统和/或新型PKC在维持这种下调中不发挥主要作用。《英国药理学期刊》(2004年)141卷,391 - 398页。doi:10.1038/sj.bjp.0705625